Immunological Responses and Therapeutic Modulation in Viral Infections: From Acute Disease to Latency

A special issue of Immuno (ISSN 2673-5601). This special issue belongs to the section "Infectious Immunology and Vaccines".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 1093

Special Issue Editor


E-Mail Website
Guest Editor
Department of Applied Ecology, Faculty of Environmental Sciences, Czech University of Life Sciences Prague, Kamýcká 129, 165 00 Prague, Czech Republic
Interests: gene; infectious diseases; herpesviruses; pharmacology and toxicology; molecular medicine; oncology and hematology; cardiovascular diseases; natural products; drug discovery; analytical and bioanalytical techniques
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Viral infections continue to present complex challenges to human health, from rapidly evolving pandemics to chronic, lifelong infections. The interplay between viral pathogens and the host immune system determines the trajectory of infection: whether the virus is cleared, persists in latency, or causes immunopathology. Recent advances in immunology, molecular virology, and therapeutic immunomodulation have transformed our understanding of how the immune system responds to viral invasion and how viruses, in turn, evolve to evade or subvert these defenses.

Acute viral infections such as those caused by SARS-CoV-2, influenza virus, or Ebola virus often trigger intense inflammatory responses, sometimes culminating in cytokine storms and tissue damage. Conversely, viruses such as herpesviruses, hepatitis B virus (HBV), and human immunodeficiency virus (HIV) have developed sophisticated mechanisms to persist in the host, evade immune surveillance, and establish latency. The immune responses in these contexts differ dramatically, ranging from hyperactivation to exhaustion or immune tolerance.

This Special Issue will provide a comprehensive overview of the immune responses involved in various viral infections, spanning from acute to latent phases, and to highlight novel immunotherapeutic strategies. We invite contributions exploring the following:

  • Innate and adaptive immunity in response to viral infections;
  • Immune evasion mechanisms employed by viruses to establish persistence;
  • Immunopathology and inflammation in acute and chronic viral diseases;
  • Vaccine responses, including next-generation and mRNA vaccines;
  • Cytokine networks, immune checkpoints, and T-cell exhaustion;
  • Host genetic and epigenetic factors influencing immune responses;
  • Viral latency and reactivation, including the role of immune control and escape;
  • Immunomodulatory therapies and their potential to enhance viral clearance or suppress pathological inflammation.

By gathering original research, reviews, and perspectives from virology, immunology, and clinical disciplines, this Special Issue will advance our understanding of how viral infections shape and are shaped by the immune system. The collected articles will provide insights into current immunotherapeutic approaches, identify gaps in our knowledge, and offer directions for future research to improve viral disease outcomes through immune-based interventions.

We welcome submissions that address mechanistic studies, translational research, clinical trials, and emerging technologies to deepen our understanding of immunological processes in viral infections.

Dr. Sherif T.S. Hassan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral immunology
  • host–virus interactions
  • immune evasion
  • viral latency
  • immunopathology
  • cytokine storm
  • T-cell exhaustion
  • immunotherapy
  • vaccine responses
  • chronic viral infections
  • antiviral immunity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 2053 KB  
Communication
Development of a Multiplexed Fluorescent Pseudovirus Neutralization Test for Simultaneous Assessment of Immunity to Three SARS-CoV-2 Variants
by Sofia M. Gulova, Alina E. Ershova, Alexander N. Shumeev, Sophia N. Rizatdinova, Alexandra V. Pavlova, Daria A. Bogdanova and Irina V. Astrakhantseva
Immuno 2026, 6(1), 17; https://doi.org/10.3390/immuno6010017 - 12 Mar 2026
Viewed by 290
Abstract
In the post-pandemic era, monitoring adaptive immunity of the population to emerging SARS-CoV-2 variants remains an important public health priority. To address this need, we developed a test that can simultaneously assess the neutralization ability of three SARS-CoV-2 variants. A panel of lentiviral [...] Read more.
In the post-pandemic era, monitoring adaptive immunity of the population to emerging SARS-CoV-2 variants remains an important public health priority. To address this need, we developed a test that can simultaneously assess the neutralization ability of three SARS-CoV-2 variants. A panel of lentiviral pseudoviruses, each bearing the S-protein of different SARS-CoV-2 variants (Wuhan-Hu-1, BA.1, and XBB.1.5) and expressing a unique fluorescent protein (Clover, mRhubarb713, or mRuby3) was generated and used to transduce hACE2-overexpressing cells. The percentage of infected target cells for each variant was quantified via flow cytometry. Co-infection led to a minor reduction in the percentage of infected cells compared to mono-infection controls, confirming the robustness of the assay. We then applied the test to the analysis of human sera samples, which were collected in the Sirius Federal Territory (Russian Federation) and revealed the following: (1) sera collected in 2021 neutralized the Wuhan-Hu-1 variant and demonstrated cross-specificity to the BA.1 variant, but not to the XBB.1.5 variant; (2) sera collected after the Omicron emergence point neutralized Wuhan-Hu-1 and BA.1, and possessed a weak ability to neutralize the XBB.1.5. This assay provides a valuable tool for efficient profiling of humoral immunity and monitoring its development in response to ongoing viral diversity. Full article
Show Figures

Figure 1

Review

Jump to: Research

17 pages, 590 KB  
Review
Advances in Antibody Engineering for Therapeutic Development: Molecular Strategies and Clinical Applications
by Olalekan Chris Akinsulie, Sinem Ulusan, Ibrahim Idris, Sammuel Shahzad, James Okon, Chizaram Ukauwa, Moyinoluwa Oladoye, Victor Aliyu, Charles Egede Ugwu, Toyin Ayandokun, Roberta Koku, Jesuferanmi Mary Akinsulie, Muhammad Ipoola Adeyemi, Charity Chinonso Ugwu and Lilian Chizobam Ugorji
Immuno 2026, 6(2), 23; https://doi.org/10.3390/immuno6020023 - 2 Apr 2026
Viewed by 354
Abstract
Antibodies are highly specialized glycoproteins produced by B cells in response to antigenic stimulation. They are a major component of the adaptive immune system and play a key role in host defenses by detecting, neutralizing, and eliminating foreign antigens. Over the years, their [...] Read more.
Antibodies are highly specialized glycoproteins produced by B cells in response to antigenic stimulation. They are a major component of the adaptive immune system and play a key role in host defenses by detecting, neutralizing, and eliminating foreign antigens. Over the years, their roles have transcended mere immune biomarkers due to their unique specificity, affinity maturation, and structural versatility, making them indispensable tools in biomedical research, including vaccine design, therapeutic development, and diagnostics. In this work, we examine the structural and functional basis of antibody bioactivity while highlighting key engineering strategies, including Fc modification, glycosylation engineering, and the development of novel antibody formats. We also considered the application of engineered antibodies in infectious disease and cancer prevention and treatment, focusing on current challenges, and proposing emerging directions that position antibody engineering as a transformative approach in future biomedical research and innovation. Full article
Show Figures

Figure 1

Back to TopTop